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Abstract
Objective The anticancer drug docetaxel is exten-
sively metabolized by cytochrome P450 (CYP) 3A iso-
zymes. Furthermore, docetaxel is also a substrate for
the transmembrane ATP-binding cassette eZux trans-
porter protein ABCB1. CYP3A-inhibition signiWcantly
reduces docetaxel total systemic clearance, on average
by 50%. However, data on the eVect of CYP3A-inhibi-
tion on the fecal and urinary excretion of docetaxel are
lacking. To further elucidate the role of CYP3A- and
ABCB1-mediated elimination pathways for docetaxel
we investigated the eVect of the potent CYP3A-inhibi-
tor, and also ABCB1-inhibitor, ketoconazole on the
fecal and urinary disposition of docetaxel in cancer
patients.
Methods Fifteen patients were treated with docetaxel
(100 mg/m2), followed 3 weeks later by a reduced dose
in combination with orally administered ketoconazole,
or vice versa. Six patients were also administered [3H]-
radiolabeled docetaxel. Fecal and urinary specimens,
collected up to 72-h post-infusion, were analyzed for
cumulative parent drug and radioactivity excretion.
Results Ketoconazole coadministration increased
fecal parent drug excretion twofold from 2.6 § 2.8 to
5.2 § 5.4% (mean § SD, P = 0.03) but did not aVect
urinary parent drug excretion (P = 0.69). The sum of
fecal and urinary parent drug excretion was 5.3 § 3.0%
for docetaxel alone and 7.8 § 5.6% in the presence of
ketoconazole, respectively (P = 0.04). Total recovered
radioactivity values were 45.8 § 19.1 and 32.4 § 19.7%,
respectively (P = 0.23).
Conclusion CYP3A-inhibition by ketoconazole
increases fecal parent drug excretion twofold in cancer
patients. A more pronounced increase was not
achieved, most likely due to concomitant intestinal
ABCB1-inhibition.
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Introduction
In recent years, the clinical pharmacokinetics (PK) of
the anticancer drug docetaxel has been subject of
thorough investigation. After intravenous administra-
tion the drug is extensively metabolized by hepatic
and intestinal cytochrome P450 (CYP) isozymes 3A
[1, 2], the catalytic activity of which is represented by
two major isoforms, CYP3A4 and CYP3A5, albeit
that CYP3A4 is the most active, possesses the highest
aYnity for docetaxel [3] and is predominant in Cauca-
sians [4]. Moreover, CYP3A activity is readily
induced or inhibited by a broad range of compounds.
Docetaxel is also a substrate for the ATP-binding
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glycoprotein; MDR-1) which acts as a (drug/xenobi-
otic-)eZux pump [5, 6], ABCB1 is expressed in sev-
eral tissues including the renal tubule, biliary tract
and intestinal epithelium [7] and plays a prominent
role in the fecal elimination of docetaxel [8, 9].
Preclinical studies with [14C]-radiolabeled docetaxel
have demonstrated that administered radioactivity is
predominately (85–95%) excreted in the feces within
7 days and that urinary excretion accounts for less than
5% [10–12]. Furthermore, the administered dose is pri-
marily (¸75%) excreted as four pharmacologically
inactive metabolites [13] and less than 10% is excreted
unchanged [14]. Clinical studies assessing excretion of
[14C]-radiolabeled docetaxel are limited; in cancer
patients (N = 3) approximately 80% of total adminis-
tered radioactivity was excreted in feces collected up to
7 days post-infusion and 5% of total radioactivity was
recovered in urine [15].
The fecal disposition of docetaxel in the presence of
ABCB1-inhibition has been studied previously [8], how-
ever, the eVect of inhibition of CYP3A, the drug’s major
route of inactivation, on docetaxel fecal and urinary
excretion, has never yet been evaluated. We previously
studied the eVect of concomitant orally administered
ketoconazole, a potent CYP3A-inhibitor [16] and also
weak to modest ABCB1-inhibitor [7, 17, 18], on docet-
axel plasma PK in cancer patients [19, 20]. Subsequently,
the current study was undertaken to evaluate, for the
Wrst time, the eVect of both CYP3A- and ABCB1-inhibi-
tion on docetaxel fecal and urinary excretion. The objec-
tives of the current study were therefore to evaluate the
inXuence of ketoconazole on (1) the fecal and urinary
excretion of unchanged docetaxel (parent drug), on (2)
the total fecal and urinary excretion of docetaxel using
[3H]-radiolabeled docetaxel and on (3) the mass balance
of ([3H]-radiolabeled-)docetaxel.
Wide variation in total CYP3A activity exists, as reX-
ected by substantial interindividual PK variability for
CYP3A substrates [21]. Part of this variability has been
related to genetic diversity in the genes encoding
CYP3A4 and CYP3A5 proteins [22]. However, currently,
most evidence infers that it is unlikely that CYP3A4 sin-
gle nucleotide polymorphisms (SNPs) contribute substan-
tially to variability in CYP3A4 activity in vivo [23–25] due
to the low frequency of genetic polymorphisms. On the
other hand, more than 80% of Caucasians is deWcient in
CYP3A5 activity due to the CYP3A5*3C/*3C variant
genotype [4]. In individuals with at least one CYP3A5*1
allele, CYP3A5 may account for at least 50% of total
CYP3A content, resulting in two to threefold higher
CYP3A activity in vitro [26]. Moreover, CYP3A4 and
CYP3A5 show distinct diVerences in susceptibility to
inhibition by ketoconazole [27]. ABCB1 polymorphisms
have not been shown to aVect docetaxel plasma PK [28,
29], yet their inXuence on fecal and urinary excretion is
unknown. We included CYP3A5 and ABCB1 genotyping
in our study to gain insight in the eVect of the various
SNPs on docetaxel fecal and urinary excretion. Genotyp-
ing for CYP3A4 rare polymorphisms was performed to
exclude genetic diversity in CYP3A4 activity.
We here report on the disposition of docetaxel in
the feces and urine of cancer patients, after intrave-
nous administration of the drug with and without con-
comitant oral administration of ketoconazole, a potent
inhibitor of the drug’s major route of inactivation.
Methods
Patient selection and study design
Eligibility criteria and study design have been reported
previously [19, 20]. BrieXy, cancer patients for whom no
other treatment was available were treated with two
courses of docetaxel administered as a 1-h intravenous
infusion once every 3-weeks. Initially, one course was
given at a dose of 100 mg/m2 and the other at a dose of
10 mg/m2 in combination with three 200-mg doses of
ketoconazole, orally administered once every 24 h up to
47 h after docetaxel infusion (standard-dose ketoconaz-
ole) [30]. Seven patients were treated accordingly fol-
lowed by plasma PK analysis. We observed wide
variability in the reduction of docetaxel total clearance
[19], which was attributed to variability in systemic
ketoconazole exposure. We subsequently treated patients
with a higher ketoconazole dose (400-mg every 8 h, up to
47 h after docetaxel infusion, i.e. a total of seven doses of
400-mg ketoconazole; high-dose ketoconazole) [31] in
combination with docetaxel (15 mg/m2) [20]. We hypothe-
sized that an increase in ketoconazole dose would result
in suYciently high ketoconazole exposure in each patient
and thus in maximum CYP3A-inhibition overall, thereby
reducing the variability in the extent to which docetaxel
clearance is reduced. In addition, we administered a
tracer-dose of [3H]-radiolabeled docetaxel to each patient
for radioactivity measurements in feces and urine, in the
absence and presence of high-dose ketoconazole. The
study protocol was approved by the Erasmus MC Investi-
gational Review Committee and all patients gave written
informed consent for participation.
Chemicals
Tritiated [3H]-docetaxel (1.0 mCi/mL in ethanol, spe-
ciWc activity 7.2 Ci/mmol; Moravek Biochemicals,123
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tion in ethanol absolute (>99.9%; Merck, Darmstadt,
Germany) were stored at ¡80°C prior to adding to
unlabeled docetaxel diluted in 250 mL 0.9% (w/v)
sodium chloride solution. Purity of [3H]-docetaxel was
analyzed by a reversed-phase high performance liquid
chromatography (HPLC) method with UV-detection
at 230 nm [32]. The elution proWle of the recovered
radioactivity was compared to the chromatographic
proWle of unlabeled docetaxel; the product showed no
signs of degradation or decreased purity [33].
Sample collection
During both courses, complete stool collections were
obtained up to 72 h post-infusion and stored at ¡80°C
until processing. Subsequently, weighted feces samples
were homogenized in three volumes (1:3 w/v) of phos-
phate buVered saline solution (PBS - Oxoid, Basing-
stoke, UK) using an Ultra-TurraxT25 homogenizer
(Janke&Kunkel, IKA®Labortechnik, Staufen, Ger-
many) operating at 20,500 rpm and then stored at
¡80°C prior to radioactivity measurements. Aliquots
of feces homogenates were further diluted (up to Wve-
fold) with PBS and stored at ¡80°C prior to chromato-
graphic analysis. All voided urine was collected
quantitatively during three intervals post-infusion (0–
24, 24–48, 48–72 h) and two portions from each interval
were stored at ¡80°C prior to radioactivity measure-
ments and chromatographic analysis.
Docetaxel analysis
Docetaxel was quantitated in feces and urine samples
using HPLC with tandem mass-spectrometric detec-
tion (LC-MS/MS). Prior to extraction all samples were
diluted at volume ratios of at least 1:1 up to 1:50 with
analyte-free lithium-heparinized human plasma. Here-
after, 100 L aliquots of the diluted feces or urine sam-
ple were processed and analyzed as described
previously [20]. Docetaxel feces and urine concentra-
tions were quantitated over the range of 5.00–500 ng/
mL. For quantitation of docetaxel in the patient sam-
ples, quality control (QC) samples at docetaxel con-
centrations of 5.00, 15.0, 400 and 6,000 ng/mL, the
latter QC diluted 20-fold prior to processing, were
assayed in duplicate and distributed among the calibra-
tors and samples in the analytical run. Finally, given
the volume of collected urine and the weight of the col-
lected feces samples, the absolute amount of docetaxel
excreted in each urine and feces specimen was calcu-
lated assuming that 1 g unhomogenized feces equals
1 mL.
Radioactivity measurements
Details of the development and validation of the ana-
lytical method used to quantitate radioactivity levels in
feces and urine have been reported elsewhere [33].
BrieXy, the radionuclide fraction of [3H] was obtained
after complete combustion of a known amount of sam-
ple aliquot (undiluted urine and 1:3 w/v diluted feces)
in a closed-type combustion Xask of known weight,
thus yielding a known amount of tritiated combustion
water, [3H]2O. Subsequently, liquid scintillation (LS)
cocktail was added to a quantitatively taken amount of
[3H]2O, the solution then mixed until homogeneous
and the samples counted in a LS-counter. Finally,
based on the amount of radioactivity in the produced
[3H]2O, the excreted radioactivity in the combusted
samples was determined and thus the total amount of
recovered radioactivity in the collected feces and urine
specimens. As [3H]-radiolabeled docetaxel is metabo-
lized and eliminated identically to unlabeled drug, the
recovered radioactivity reXects the sum of radioactivity
from excreted parent drug and all excreted metabo-
lites.
Genotype analysis
Polymerase chain reaction (PCR)-restriction fragment
length polymorphism analysis for CYP3A5*3C,
CYP3A5*6, CYP3A4*1B, CYP3A4*3, CYP3A4*17,
CYP3A4*18A and ABCB1 3435C > T variant alleles
was performed as described previously [4, 34, 35].
Based on allele frequencies in the Caucasian popula-
tion, in which the CYP3A5*3C allele is the predomi-
nant allele, the rare CYP3A5*6 variant allele, which
also results in completely or severely decreased
CYP3A5 activity was only determined for individuals
with no, or only one CYP3A5*3C allele (i.e. with
apparently at least one CYP3A5*1 allele).
Statistical considerations
Excretion parameters are reported as mean
values § SD unless stated otherwise. The diVerence in
parameters between the two courses was evaluated sta-
tistically using a non-parametric two-tailed, Wilcoxon
signed rank test for paired observations after testing
for period eVects. Mean (§SD) urinary parent drug
excretion values for the standard- and high-dose
ketoconazole patient-groups were 2.2% (§0.95) and
3.0% (§1.09), respectively. Mean (§SD) fecal parent
drug excretion values for the standard- and high-dose
ketoconazole patient-groups were 5.5% (§5.41) and
4.8% (§5.77), respectively. Subsequent comparison of123
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the presence of ketoconazole) between the standard-
and high-dose ketoconazole patient-groups showed no
signiWcant diVerences (P = 0.17 and P = 0.95 respec-
tively, Mann–Whitney U-test). Furthermore, the extent
to which docetaxel total clearance was reduced was
almost identical for high- and standard-dose ketoconz-
ole treatment [19, 20] suggesting that the increase in
ketoconazole dose did not augment the extent of
CYP3A-inhibition. Therefore, the excretion data of all
patients were evaluated together, irrespective of
ketoconazole dose. The signiWcance level was set at
P < 0.05. Statistical calculations were performed with
SPSS version 11.5 (Chicago, IL, USA).
Results
Baseline patient proWles
A total of 15 Caucasian patients were included (stan-
dard-dose ketoconazole, N = 7; high-dose ketoconaz-
ole, N = 8). For all patients urine samples were
collected during both courses. For one patient (high-
dose ketoconazole group) no feces samples were col-
lected, thus feces samples were available for 14
patients during both courses. None of the patients were
administered CYP3A- inducing or inhibiting co-medi-
cation, however two patients were administered medi-
cation known to reduce ketoconazole gastro-intestinal
absorption (pantoprazole and ranitidine), thus (poten-
tially) decreasing systemic ketoconazole exposure [36].
For the patient administered pantoprazole (and high-
dose ketoconazole) ketoconazole exposure (area
under the concentration-time curve, AUC) was
approximately fourfold higher than median exposure
(AUC = 60.1 mg £ h/L; range 19.6–81.3 mg £ h/L) for
patients treated with standard-dose ketoconazole
(without interfering medication). As previously dis-
cussed, we did not observe a signiWcant diVerence in
docetaxel urinary and fecal excretion in the presence of
ketoconazole between standard- or high-dose ketoco-
nazole, therefore this patient was included in our anal-
ysis. Of note, this was also the patient for whom no
feces samples were available. For the patient adminis-
tered ranitidine (and standard-dose ketoconazole),
ketoconazole exposure was indeed the lowest
(AUC = 12.8 mg £ h/L), yet diVered only marginally
from the exposure (AUC = 19.6 mg £ h/L) for another
patient not administered interfering co-medication.
Furthermore, for this patient, fecal parent drug excre-
tion in the presence of ketoconazole was increased by
44% suggesting an inhibitory eVect of ketoconazole.
We therefore also included this patient in our analysis.
Thus, 15 patients were evaluable for cumulative urinary
parent drug excretion-analysis and 14 for cumulative
fecal parent drug excretion-analysis. Urine and feces
samples for radioactivity measurements were available
for six and Wve patients, respectively, in the absence and
presence of high-dose ketoconazole. Table 1 summarizes
the baseline characteristics for the evaluable patients.
All patients were genotyped for CYP3A5*3C,
CYP3A4*1B, CYP3A4*3, CYP3A4*17 and
CYP3A4*18A variant alleles. Fourteen patients were
homozygous for the CYP3A5*3C variant allele, and con-
sequently deWcient in CYP3A5 activity, indicating that
for these patients total hepatic and intestinal CYP3A
activity is solely attributable to CYP3A4 activity. Only
CYP3A5 (not CYP3A4) is expressed to any signiWcant
degree in renal tubular epithelial cells [37]. Thus for the
CYP3A5*3C homozygous individuals, any eVect of
ketoconazole on urinary parent drug excretion cannot be
attributed to CYP3A(5)-inhibition. One patient carried a
single CYP3A5*1 allele, yet not the CYP3A5*6 variant
allele, indicating that in this patient CYP3A5 is (most
probably) active. This same patient was the only het-
erozygous carrier of the CYP3A4*1B variant allele
(*1A/*1B). All other patients were homozygous
Table 1 Baseline patient characteristics
Values are given as median with range in parentheses (except for
sex and tumor type)
WHO World Health Organization, WBC white blood cell count,
ANC absolute neutrophil count, ASAT aspartate aminotransfer-
ase, ALAT alanine aminotransferase, Alk Phos alkaline phos-
phatase, AAG 1-acid glycoprotein
Characteristic Value 
Number 15 
Age (years) 50 (36–69)
Sex (male/female) 11 / 4 
Body-surface area (m2) 1.89 (1.55–2.19)
WHO performance status 1 (0–1)
Tumor type






WBC (£109/L) 8.2 (5.7–14.9)
ANC (£109/L) 6.8 (3.2–12.3)
Platelets (£109/L) 264 (156–930)
Hemoglobin (mmol/L) 8.3 (5.8–9.2)
ASAT (U/L) 25 (17–79)
ALAT (U/L) 20 (6–30)
Alk Phos (U/L) 77 (58–241)
Total Bilirubin (M) 6 (4–15)
Serum Albumin (g/L) 41 (28–46)
Serum AAG (g/L) 1.03 (0.86–1.67)123
Cancer Chemother Pharmacol (2007) 60:569–579 573CYP3A4*1A/*1A. No patients carried variant alleles for
CYP3A4*3, CYP3A4*17 or CYP3A4*18A. ABCB1
3435C > T genotyping results were available for 13
patients. The genotype distribution was one homozygous
wild-type patient (C/C), eight heterozygous variant patients
(C/T) and four homozygous variant patients (T/T).
Fecal and urinary parent drug excretion
A summary of the cumulative excretion of parent drug
in feces and urine collected up to 72 h post-infusion
during both courses is listed in Tables 2 and 3. Data are
reported as total fraction (i.e. percentage) of the
administered absolute docetaxel dose which is excreted
unchanged in the feces (fef,%) or urine (feu,%). After
single agent dosing a minor fraction of the adminis-
tered docetaxel dose was recovered in the feces
unchanged (2.6 § 2.8%). Total fecal parent drug excre-
tion was approximately twofold higher in the presence
of ketoconazole (5.2 § 5.4%, P = 0.03). We observed a
trend toward statistical signiWcance when the fecal par-
ent drug excretion in the absence and presence of
ketoconazole was evaluated for each 24-h interval (0–
24 h, P = 0.87, N = 7; 24–48 h, P = 0.52, N = 9; 48–72 h,
P = 0.03, N = 6). Fecal specimens were not available
for every patient in each 24-h interval, explaining why
the number of patients included in these sub-analyses
is less than the 14 evaluable patients. Furthermore, this
also explains why the sum of the average fraction of par-
ent drug excreted during each 24-h period does not equal
the total cumulative fecal parent drug excretion (0–72 h).
Figure 1a shows the cumulative fecal parent drug
excretion in the absence of ketoconazole as a function
of CYP3A4*1B, CYP3A5*3C and ABCB1 3435C > T
genotype. Mean fecal parent drug excretion for the
CYP3A5*3C and CYP3A4*1A homozygous patients
was 2.6 and 2.4% for the single CYP3A5*3C and
CYP3A4*1B heterozygous patient. The genotype dis-
tribution (13 vs. 1) does not allow statistical evaluation,
however, these data do not suggest a substantial diVer-
ence in fecal excretion for the evaluated genotypes.
Mean fecal parent drug excretion for the C/T and T/T
ABCB1 genotypes was 2.6 and 4.2%, respectively
(P = 0.85). Fecal excretion for the patient with C/C
genotype was 1.3%.
The cumulative urinary parent drug excretion did
not diVer signiWcantly between the two courses
(P = 0.69) and renal parent drug excretion predomi-
nantly (>80%) took place during the Wrst 24 h post-
infusion regardless of ketoconazole administration
(Table 3). The ratio of the fraction of parent drug
excreted during the Wrst 24 h to the total fraction of
excreted parent drug (feu0–24 h:feu0–72 h) was signiW-
cantly lower in the presence of ketoconazole (P = 0.02,
N = 15). This was also the case when we evaluated this
ratio for patients administered high-dose ketoconazole
separately (P = 0.01), yet not for patients administered
standard-dose ketoconazole (P = 0.93).
Figure 1b shows the cumulative urinary parent drug
excretion in the absence of ketoconazole as a function
of CYP3A4*1B, CYP3A5*3C and ABCB1 3435C > T
genotype. Mean urinary parent drug excretion for the
CYP3A5*3C and CYP3A4*1A homozygous patients
was 2.6 and 2.8% for the CYP3A5*3C and CYP3
A4*1B heterozygous individual, again not suggesting a
substantial diVerence between the evaluated geno-
types. Mean urinary parent drug excretion for the C/T
Table 2 Cumulative fecal excretion of parent drug
Values are given as mean § SD with range in parentheses
Ketoconazole = 0 ketoconazole absent, Ketoconazole = 1 ketoco-
nazole present, fef cumulative fecal parent drug excretion ex-
pressed as percentage of the absolute docetaxel dose
administered
Parameter Ketoconazole = 0 Ketoconazole = 1 P-value 
fef (%) 0–72 h, 
N = 14
2.6 § 2.8 
(0.02–10.0)
5.2 § 5.4 
(0.04–14.3)
<0.05
fef (%) 0–24 h, 
N = 7
1.7 § 3.1 
(0.03–8.7)
1.7 § 2.4 
(0.08–6.7)
0.87
fef (%) 24–48 h, 
N = 9
1.8 § 1.4 
(0.01–3.91)
2.7 § 2.2 
(0.37–6.6)
0.52
fef (%) 48–72 h, 
N = 6
0.74 § 0.41 
(0.01–1.1)
3.0 § 1.9 
(1.1–5.5)
<0.05
Table 3 Cumulative urinary excretion of parent drug 
Values are given as mean § SD with range in parentheses
Ketoconazole = 0 ketoconazole absent, Ketoconazole = 1 ketoco-
nazole present, feu cumulative urinary parent drug excretion ex-
pressed as percentage of the absolute docetaxel dose
administered, ratio feu0–24 h : feu0–72 h ratio of the urinary excre-
tion of parent drug during the Wrst 24 h to the total urinary excre-
tion of parent drug up to 72 h post-infusion
Parameter Ketoconazole = 0 Ketoconazole = 1 P-value 
feu (%) 0–72 h, 
N = 15
2.6 § 1.4 
(1.3–5.7)
2.6 § 1.1 
(1.1–5.0)
0.69
ratio feu0–24 h : 
feu0–72 h, 
N = 15 
0.94 § 0.03 
(0.86–0.97)
0.88 § 0.07 
(0.78–1.00)
<0.05
ratio feu0–24 h : 
feu0–72 h, 
N = 7 
(standard-dose 
ketoconazole)
0.93 § 0.04 
(0.86–0.97)
0.93 § 0.07 
(0.84–1.00)
0.93
ratio feu0–24 h : 
feu0–72 h, 
N = 8 
(high-dose 
ketoconazole)
0.95 § 0.02 
(0.91–0.97)
0.83 § 0.04 
(0.78–0.89)
<0.05123
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tively, (P = 0.04). Urinary excretion for the patient
with C/C genotype was 5.2%.
Radioactivity recovered in feces and urine
A summary of the cumulative radioactivity recovered in
feces (Raf,%) and urine (Rau,%) samples collected up
to 72 h post-infusion during both treatments is listed in
Table 4. Mean cumulative fecal excretion of radioactiv-
ity was lower in the presence of ketoconazole (27.7%
vs. 40.4%), but this diVerence was not signiWcant
(P = 0.23). Mean fecal parent drug excretion in the
presence and absence of ketoconazole was 6.7 and 3.3%
(for these Wve patients), respectively, suggesting that
the fraction of excreted metabolites in the presence and
absence of ketoconazole was 21.0 and 37.1%, respectively
(P = 0.14). We evaluated the inXuence of ketoconazole
on the ratio of fecal parent drug excretion to fecal
excretion of parent drug and all metabolites, the latter
reXected by cumulative radioactivity excretion. This
ratio (fef:Raf) was signiWcantly higher (P = 0.04) in the
presence of ketoconazole (0.26 § 0.09) compared to
single agent docetaxel (0.10 § 0.05), conWrming the
observed increased parent drug excretion.
The total fraction of radioactivity recovered in urine
did not diVer signiWcantly between the two courses
(P = 0.17). For both courses, the percentage of urinary
recovered radioactivity is approximately 2% higher
than cumulative urinary parent drug excretion, sug-
gesting that approximately 2% of the administered
docetaxel dose is eliminated renally as metabolite(s).
The ratio of the cumulative fraction of radioactivity
recovered in urine during the Wrst 24 h to the total frac-
tion of urinary excreted radioactivity (ratio Rau0–
24 h:Rau0–72 h) was signiWcantly lower in the course
Fig. 1 Box plots of the percentage cumulative fecal parent drug
excretion (a) and cumulative urinary parent drug excretion (b) as
a function of CYP3A5*3C, CYP3A4*1B and ABCB1 C3435T
genotype; (1) denotes CYP3A5*3C homozygous variant allele
carriers and patients carrying no CYP3A4*1B variant allele (i.e.
CYP3A4*1A/*1A, N = 14); (2) denotes CYP3A5*3C heterozy-
gous variant allele carriers and CYP3A4*1B heterozygous vari-
ant allele carriers (N = 1); C/C denotes ABCB1 homozygous
wild-type allele carriers (N = 1), C/T denotes patients carrying
one variant allele (N = 8) and T/T denotes homozygous variant
allele carriers (N = 4). The box represents the diVerence between
the 25th and 75th percentiles (i.e. the interquartile range), where-
as the horizontal line inside the box represents the median. Open
circles are deWned as outliers. Whiskers are drawn from the ends
of the box to the largest and smallest values that are not outliers123
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excretion data, ketoconazole did not inXuence the ratio
of urinary parent drug excretion to urinary excretion of
parent drug and all metabolites (feu:Rau; P = 0.27).
Mass balance
The mass balances of excreted parent drug and recov-
ered radioactivity (determined by adding the cumula-
tive fecal and urinary excretion data) for each course
are summarized in Table 5. For parent drug total
cumulative excretion is signiWcantly higher in the pres-
ence of ketoconazole (P = 0.04). The mass balance of
recovered radioactivity was lower in the course with
ketoconazole, yet the diVerence was not signiWcant
(P = 0.23).
Mean cumulative total parent drug excretion for the
CYP3A5*3C and CYP3A4*1A homozygous patients
was 5.3 and 5.2% for the CYP3A5*3C and
CYP3A4*1B heterozygous individual. Mean cumula-
tive total parent drug excretion for the C/T and T/T
ABCB1 genotypes was 5.5 and 5.8%, respectively
(P = 1.0). Cumulative total parent drug excretion for
the patient with C/C genotype was 6.5%.
Discussion
Although docetaxel plasma PK in cancer patients is well
characterized, data on the fecal and urinary excretion of
the drug are limited. In this study we evaluated the fecal
and urinary excretion of docetaxel parent drug and [3H]-
radiolabeled docetaxel in cancer patients, after intrave-
nous docetaxel administration with and without con-
comitant orally administered ketoconazole, a potent
inhibitor of CYP3A-mediated metabolism, the drug’s
major route of inactivation and also a (weak to modest)
inhibitor of ABCB1, which plays an important role in
the fecal disposition of docetaxel [8, 9]. Assessing pur-
poseful modulation of docetaxel fecal and urinary dispo-
sition can contribute to a better overall understanding of
the mechanistic aspects involved in docetaxel metabo-
lism. Recently, hepatic CYP3A-induction in vitro led to
CYP2C8-mediated formation of a previously unidenti-
Wed docetaxel metabolite [38]. Furthermore, preliminary
data indicate that renal function (creatinine clearance) is
the most signiWcant predictor of docetaxel clearance in
the presence of ketoconazole (Pearson’s correlation
coeYcient, R = 0.484; P = 0.002) [39], which is in con-
trast with single agent treatment where hepatic function
is a signiWcant predictor of docetaxel clearance [40, 41].
In the absence of ketoconazole, fecal parent drug
excretion was consistent with previous Wndings [9] and
approximately twofold increased in the presence of
ketoconazole. The relative contribution of ABCB1-inhi-
bition is quantitatively less signiWcant than the contribu-
tion of CYP3A-inhibition to the overall eVect of
ketoconazole-mediated drug interactions [7, 17, 18].
Thus, the here observed drug-interaction should primar-
ily be attributed to CYP3A-inhibition, however the
inXuence of concomitant ABCB1-inhibition should not
be overlooked. In the presence of a selective ABCB1-
inhibitor re-absorption of docetaxel parent drug from
the intestinal lumen (following biliary secretion) is a
very eYcient process and subsequent CYP3A-mediated
Table 4 Cumulative radioactivity recovered in feces and urine
Values are given as mean § SD with range in parentheses
Ketoconazole = 0 ketoconazole absent, Ketoconazole = 1 ketoco-
nazole present, Raf, Rau cumulative radioactivity recovered in fe-
ces and urine, respectively, expressed as percentage of the
absolute amount of added radioactivity, ratio fef : Raf ratio of total
fecal excretion of parent drug to total fecal excretion of parent
drug and all metabolites, ratio feu : Rau ratio of total urinary
excretion of parent drug to total urinary excretion of parent drug
and all metabolites, ratio Rau0–24 h : Rau0–72 h ratio of recov-
ered urinary radioactivity during the Wrst 24 h to total recovered
urinary radioactivity up to 72 h post-infusion
Parameter Ketoconazole = 0 Ketoconazole = 1 P-value 
Raf (%) 0–72 h, 
N = 5 
40.4 § 19.9 
(7.37–55.8)
27.7 § 20.3 
(1.17–45.5)
0.23
ratio fef : Raf, 
N = 5 
0.10 § 0.05 
(0.05–0.17)
0.26 § 0.09 
(0.12–0.35)
<0.05 
Rau (%) 0–72 h, 
N = 6 
5.13 § 1.23 
(3.76–6.94)
4.52 § 1.38 
(3.48–7.14)
0.17
ratio Rau0–24 h : 
Rau0–72 h, 
N = 6
0.89 § 0.04 
(0.82–0.93)
0.78 § 0.05 
(0.72–0.86)
<0.05
ratio feu: Rau, 
N = 6
0.59 § 0.22 
(0.28–0.83)
0.66 § 0.11 
(0.52–0.81)
0.27
Table 5 Mass balance parent drug excretion and mass balance
recovered radioactivity
Values are given as mean § SD with range in parentheses
Ketoconazole = 0 ketoconazole absent, Ketoconazole = 1 ketoco-
nazole present, fef, feu cumulative excretion of parent drug in fe-
ces and urine, respectively, expressed as percentage of the
absolute docetaxel dose administered, Raf, Rau cumulative radio-
activity recovered in feces and urine, respectively, expressed as
percentage of the absolute amount of added radioactivity
Parameter Ketoconazole = 0 Ketoconazole = 1 P-value 
Mass 
balance (%) 
0–72 h, N = 14 
(fef + feu)
5.3 § 3.0 
(1.3–11.3)





0–72 h, N = 5 
(Raf + Rau)
45.8 § 19.1 
(13.7–60.4)
32.4 § 19.7 
(5.4–49.5)
0.23123
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consequently leads to a marked reduction in fecal parent
drug excretion [8, 9]. If theoretically, ketoconazole was
to act only as a selective CYP3A-inhibitor, adequate
ABCB1-mediated eZux of parent drug into the intesti-
nal lumen would not be impaired. Consequently, due to
ketoconazole-mediated selective CYP3A-inhibition,
one would expect the administered docetaxel dose to be
excreted predominantly as parent drug. Concomitant
ketoconazole-mediated ABCB1-inhibition most likely
explains why we did not observe a more marked
increase in fecal parent drug excretion in the presence of
ketoconazole (Fig. 2: a schematic representation of the
role of hepatic CYP3A and intestinal ABCB1 in docet-
axel metabolism and excretion and the inhibitory eVect
of ketoconazole). Interestingly, we observed a trend
toward a statistically signiWcant diVerence in fecal parent
drug excretion in the presence and absence of ketoco-
nazole as the time-interval post-infusion increased. The
eVect of ABCB1-inhibition is expected to be most pro-
nounced shortly after ketoconazole administration due
to high local drug concentrations in the gut, and to
decrease over time, such that in the 48–72 h interval,
when no ketoconazole was administered, the (relative)
contribution of ketoconazole-mediated CYP3A-inhibi-
tion is more pronounced than in the 0–24 h interval.
A second consequence of temporarily inhibiting
CYP3A-mediated metabolism is a reduction in the
fraction of formed metabolites. The diVerence between
fecal recovered radioactivity (i.e. parent drug and all
excreted metabolites) and fecal parent drug excretion
reXects the fecal excretion of metabolites. We observed
a lower fraction of excreted metabolites in the pres-
ence of ketoconazole (21.0 vs. 37.1%), although the
diVerence was not statistically signiWcant (P = 0.14).
The lack of signiWcance is possibly also a consequence
of concomitant ABCB1-inhibition or because alterna-
tive routes of metabolism then prevail or due to our
limited sample size (N = 5).
The cumulative fraction of fecal recovered radioac-
tivity was not signiWcantly lower in the presence of
ketoconazole (P = 0.23). This is in line with the concept
of mass conservation, stating that (tritium-labeled)
mass is neither created nor destroyed during a
Fig. 2 Schematic representation of the role of hepatic CYP3A
and intestinal ABCB1 in docetaxel metabolism and elimination
in humans and ketoconazole-mediated inhibition. a Model of the
hepatic-cellular plate showing the bile collecting system with (1)
inhibition by ketoconazole (depicted by a cross) of cytochrome
P450 3A isozyme-mediated hepatic metabolism of docetaxel
from the systemic circulation or the portal vein after re-absorp-
tion following biliary secretion and (2) its subsequent secretion in
the terminal bile duct. b Model of the intestinal epithelium show-
ing (1) re-uptake of docetaxel into the intestinal lumen, (2)
ABCB1-mediated eZux of docetaxel and its inhibition by ketoco-
nazole (depicted by a cross) and (3) intestinal metabolism by the
cytochrome P450 3A enzyme system and its inhibition by ketoco-
nazole (depicted by a cross). Abbreviations: ABCB, ABCB1;
doc, docetaxel; keto, ketoconazole; M, docetaxel metabolite M4;
CYP3A, enzymes of the cytochrome P450 family, isoform 3A123
Cancer Chemother Pharmacol (2007) 60:569–579 577chemical reaction, i.e. metabolism. Thus, despite
CYP3A-inhibition, the total fraction of excreted par-
ent drug and all metabolites (i.e. recovered radioactiv-
ity) should not diVer between the two courses.
Urinary excretion plays a minor role in the elimina-
tion of docetaxel. We determined urinary parent drug
excretion and urinary excretion of metabolites each to
be approximately 2%. Interestingly, substantially
increasing the ketoconazole dose signiWcantly reduced
parent drug excretion during the Wrst 24 h post-infu-
sion relative to total parent drug excretion (ratio feu0–
24 h:feu0–72 h). This eVect is most likely attributable to
ketoconazole-mediated ABCB1-inhibition as, with the
exception of one, all patients were deWcient in renal
CYP3A(5) activity. Ketoconazole-mediated inhibition
of ABCB1 transport function is concentration depen-
dant [42], therefore it is likely that the higher ketoco-
nazole dose eVectively inhibits ABCB1 localized on
the apical surface of renal tubular epithelial cells [43]
thereby limiting ABCB1-mediated renal parent drug
secretion. Again, (the eVect of) renal ABCB1-inhibi-
tion seems most pronounced shortly after ketoconaz-
ole administration. However, ketoconazole-mediated
ABCB1-inhibition was not marked enough to aVect
the cumulative urinary elimination of docetaxel.
The mass balance for cumulative parent drug excre-
tion was increased upon concomitant ketoconazole
administration, yet not as marked as one may have
expected, due to the discussed inXuence of concomi-
tant intestinal ABCB1-inhibition. The mass balance
for the fraction of recovered radioactivity, although
lower in the presence of ketoconazole, did not diVer
signiWcantly between the two courses, due to above-
mentioned reasons.
To our knowledge, the fecal and urinary excretion of
docetaxel has not previously been evaluated as func-
tion of genotype. As our patient group was limited in
size we only tentatively correlated parent drug excre-
tion (in the absence of ketoconazole) to genotype. The
mean cumulative fecal excretion for patients carrying
the ABCB1 T/T genotype was more than threefold
that observed for the (single) patient with the C/C
genotype which is consistent with data suggesting
higher expression of intestinal ABCB1 for the T/T
genotype [44]. Interestingly, the observed higher fecal
excretion for homozygous variant allele carriers (T/T)
compared to the homozygous wild-type (C/C) patient
is inversed for urinary excretion and could be a reXec-
tion of diVerent ABCB1 3435C > T expression among
tissues [44, 45].
We are aware of several limitations in our study;
(1) the number of patients was limited, especially the
sub-group administered [3H]-radiolabeled docetaxel,
yet more than in previous excretion studies using
radiolabeled docetaxel; [15] (2) specimens were col-
lected up to 72 h post-infusion, the period of hospital
admission; ideally specimens should be collected up to
7 days post-infusion yet this poses practical and logisti-
cal diYculties; (3) although patients consented to col-
lection of all fecal and urinary specimens, it is possible
that collection is not complete; (4) we did not analyze
the fecal and urinary excretion of the major metabo-
lites due to unavailability of reference compounds and
(5) it is likely that by assuming that 1 g unhomogenized
feces is equivalent to 1 mL, we have underestimated
the cumulative fecal excretion. However, despite these
limitations, this study has further elucidated the elimi-
nation pathways of docetaxel. Moreover, to the best of
our knowledge, for the Wrst time fecal and urinary
excretion of docetaxel were evaluated after temporar-
ily inhibiting the drug’s major route of inactivation.
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